In vitro, under adherent conditions, CP-d/n-ATF5 dose-dependently inhibited the growth of a panel of neuroblastoma cell lines, both MYCN-amplified and MYCN-non-amplified (Supplementary Fig. S12). Here, ATF5 is linked to neuroblastoma.